Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies, Inc. (TSHA)
:TSHA
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 1.18%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the TSHA-102 program, including the completion of Part A dosing and encouraging safety and functional outcomes, alongside strong financial positioning. Despite increased R&D expenses and a net loss, the overall sentiment is positive due to the promising clinical and regulatory advancements.Company Guidance
During the conference call, Taysha Gene Therapies provided guidance on several key metrics and developments for their TSHA-102 program. The company highlighted the completion of dosing for ten patients in Part A of their REVEAL Phase 1/2 trials, with six patients receiving a high dose of 1e15 total vector genomes and four patients a low dose of 5.7e14 total vector genomes. The safety profile was encouraging, with no treatment-related serious adverse events or dose-limiting toxicities observed. Financially, Taysha reported R&D expenses of $66 million and a net loss of $89.3 million for 2024, with $139 million in cash reserves expected to support operations into Q4 2026. The company plans to advance TSHA-102 towards a pivotal Part B trial, focusing on functional gains in Rett syndrome, and anticipates updates on trial design and clinical data in the first half of 2025.Completion of Part A Dosing
TSHA-102 has completed dosing of ten patients in Part A, including six in the high dose cohort and four in the low dose cohort, demonstrating an encouraging safety profile with no treatment-related serious adverse events or dose-limiting toxicities.
Positive Safety Profile
TSHA-102 was generally well tolerated across all dosed patients, with no treatment-related SAEs or DLTs observed, which is encouraging for advancing to the pivotal phase.
Encouraging Functional Gains
Patients treated with TSHA-102 demonstrated functional gains such as improvements in motor function, socialization, communication, and seizure events, which are meaningful improvements for caregivers.
Strong Financial Position
Taysha Gene Therapies ended 2024 with $139 million in cash and cash equivalents, expected to support planned operations into the fourth quarter of 2026.
Regulatory Progress with FDA
Ongoing productive discussions with the FDA through the RMAT mechanism to solidify the regulatory pathway for TSHA-102, with an update on pivotal Part B trial design expected in the first half of 2025.
---
TSHA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSHA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $1.70 | $1.62 | -4.71% |
| Nov 13, 2024 | $2.21 | $2.27 | +2.71% |
| Aug 12, 2024 | $2.09 | $2.04 | -2.39% |
| May 14, 2024 | $2.57 | $3.11 | +21.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Taysha Gene Therapies, Inc. (TSHA) report earnings?
Taysha Gene Therapies, Inc. (TSHA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Taysha Gene Therapies, Inc. (TSHA) earnings time?
Taysha Gene Therapies, Inc. (TSHA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSHA EPS forecast?
TSHA EPS forecast for the fiscal quarter 2025 (Q1) is -0.09.
---